Quantum BioPharma Ltd. - Asset Resilience Ratio
Quantum BioPharma Ltd. (QNTM) has an Asset Resilience Ratio of 4.50% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Quantum BioPharma Ltd.'s Asset Resilience Ratio has changed over time. Check QNTM PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Quantum BioPharma Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Quantum BioPharma Ltd. (QNTM) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $636.76K | 4.5% |
| Total Liquid Assets | $636.76K | 4.50% |
Asset Resilience Insights
- Limited Liquidity: Quantum BioPharma Ltd. maintains only 4.50% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Quantum BioPharma Ltd. Industry Peers by Asset Resilience Ratio
Compare Quantum BioPharma Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Quantum BioPharma Ltd. (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Quantum BioPharma Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 7.02% | $1.20 Million | $17.12 Million | +2.70pp |
| 2023-12-31 | 4.33% | $756.10K | $17.47 Million | +4.27pp |
| 2022-12-31 | 0.06% | $23.19K | $38.41 Million | -0.19pp |
| 2021-12-31 | 0.25% | $158.04K | $62.96 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $41.97 Million | -- |
About Quantum BioPharma Ltd.
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in d… Read more